Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy CytomX Therapeutics stock

Learn how to easily invest in CytomX Therapeutics stock.

CytomX Therapeutics is a biotechnology business based in the US. CytomX Therapeutics shares (CTMX) are listed on the NASDAQ and all prices are listed in US Dollars. CytomX Therapeutics employs 174 staff and has a trailing 12-month revenue of around $71.9 million.

How to buy CytomX Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CTMX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Easy to use platform with low fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

CytomX Therapeutics stock price (NASDAQ: CTMX)

Use our graph to track the performance of CTMX stocks over time.

CytomX Therapeutics shares at a glance

Information last updated 2023-02-08.
Latest market close$2.75
52-week range$1.17 - $4.69
50-day moving average $2.09
200-day moving average $1.70
Wall St. target price$2.82
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.41

Buy CytomX Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$10
FINDER EXCLUSIVE: Get $15
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy CytomX Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CytomX Therapeutics price performance over time

Historical closes compared with the close of $2.75 from 2023-02-07

1 week (2023-02-02) 6.18%
1 month (2023-01-09) -4.51%
3 months (2022-11-09) 121.77%
6 months (2022-08-09) 71.88%
1 year (2022-02-05) N/A
2 years (2021-02-09) -68.61%
3 years (2020-02-07) 6.75
5 years (2018-02-09) 27

CytomX Therapeutics financials

Revenue TTM $71.9 million
Gross profit TTM $69.6 million
Return on assets TTM -19.17%
Return on equity TTM -139.27%
Profit margin -135.65%
Book value $0.43
Market capitalisation $173.5 million

TTM: trailing 12 months

CytomX Therapeutics share dividends

We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.

CytomX Therapeutics share price volatility

Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $1.17 up to $4.685. A popular way to gauge a stock's volatility is its "beta".

CTMX.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.6175. This would suggest that CytomX Therapeutics's shares are less volatile than average (for this exchange).

CytomX Therapeutics overview

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc. , Bristol-Myers Squibb Company, ImmunoGen, Inc.

Frequently asked questions

What percentage of CytomX Therapeutics is owned by insiders or institutions?
Currently 1.303% of CytomX Therapeutics shares are held by insiders and 58.755% by institutions.
How many people work for CytomX Therapeutics?
Latest data suggests 174 work at CytomX Therapeutics.
When does the fiscal year end for CytomX Therapeutics?
CytomX Therapeutics's fiscal year ends in December.
Where is CytomX Therapeutics based?
CytomX Therapeutics's address is: 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site